Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Study of GDC-0941 alone in Patients with Solid Tumors or GDC-0941 in Combination with Carboplatin / Paclitaxel + Bevacizumab in Patients with Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.

Next Previous
Trial Profile

Phase I Study of GDC-0941 alone in Patients with Solid Tumors or GDC-0941 in Combination with Carboplatin / Paclitaxel + Bevacizumab in Patients with Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 15 Oct 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pictrelisib (Primary) ; Bevacizumab; Carboplatin; Paclitaxel
  • Indications Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics

Most Recent Events

  • 27 Aug 2016 Results published in the Investigational New Drugs
  • 19 Jan 2016 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top